Several approaches are being developed to target miR-155 for cancer therapy:
Antisense Oligonucleotides (ASOs): These are short, synthetic strands of nucleic acids designed to bind to miR-155 and inhibit its function. Locked Nucleic Acid (LNA) Inhibitors: LNAs are chemically modified nucleic acids with high affinity for their target miRNAs, providing potent and specific inhibition of miR-155. Small Molecule Inhibitors: These compounds can interfere with miR-155 biogenesis or function, thereby reducing its oncogenic activity. Nanoparticle Delivery Systems: Nanoparticles can be employed to deliver miR-155 inhibitors specifically to tumor cells, enhancing therapeutic efficacy and reducing off-target effects.
